Expansion opportunities Norgine is actively expanding manufacturing capacity in the UK and Europe, including a multi-million pound investment in Wales to increase production of gastrointestinal medicines. This signals a need for scalable supply chain solutions, contract manufacturing partnerships, and related services to support capacity ramp-up and QA/QC alignment.

Strategic partnerships Recent exclusive licensing with Vir Biotechnology for hepatitis delta treatment and acquisition activity in rare diseases indicate a focus on expanding portfolio through partnerships and acquisitions. Potential sales plays include licensing, co-development, distribution rights, and specialty product commercialization support.

Operational excellence Norgine emphasizes in-house manufacturing, robust supply networks, and integrated commercial, medical, regulatory, and clinical capabilities. Opportunities exist to offer end-to-end digital transformation, manufacturing automation, supply chain analytics, and compliance solutions to sustain efficiency amid supply volatility.

Geographic reach Core markets in Western Europe, Australia, and New Zealand with expanding UK presence suggest demand for regional services, regulatory consulting, market access support, and local manufacturing adjuncts to ensure uninterrupted supply across these territories.

Portfolio diversification Recent portfolio moves include Theravia acquisition and expanded rare disease focus, alongside collaborations in gastro-intestinal therapies. This creates openings for specialty product commercialization services, patient access programs, and clinical support offerings tailored to niche indications.